EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Newly developed oral bioavailable EHMT2 inhibitor as a potential epigenetic therapy for Prader-Willi syndrome

Sung Eun Wang, Yan Xiong, Mi-Ae Jang, Kwang-Su Park, Meaghan Donahue, Julia Velez, Jian Jin, Yong-Hui Jiang

Molecular Therapy · 2024

DOI: 10.1016/j.ymthe.2024.05.034 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecular Therapy, 2024. Verfasst von Sung Eun Wang und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Genetics, Yale University School of Medicine, 333 Cedar Street, New Haven CT 06520, USA. Hauptthemen laut MEDLINE: Prader-Willi Syndrome, Epigenesis, Genetic, Disease Models, Animal. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NIH HHS, NCATS NIH HHS, NICHD NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Prader-Willi syndrome (PWS) is the prototypic genomic disorder resulting from deficiency of paternally expressed genes in the human chromosome 15q11-q13 region. The unique molecular mechanism involving epigenetic modifications renders PWS as the most attractive candidate to explore a proof-of-concept of epigenetic therapy in humans. The premise is that epigenetic modulations could reactivate the repressed PWS candidate genes from the maternal chromosome and offer therapeutic benefit. Our prior study identifies an EHMT2/G9a inhibitor, UNC0642, that reactivates the expression of PWS genes via reduction of H3K9me2. However, low brain permeability and poor oral bioavailability of UNC0642 preclude its advancement into translational studies in humans. In this study, a newly developed inhibitor, MS152, modified from the structure of UNC0642, has better brain penetration and greater potency and selectivity against EHMT2/G9a. MS152 reactivated maternally silenced PWS genes in PWS patient fibroblasts and in brain and liver tissues of PWS mouse models. Importantly, the molecular efficacy of oral administration is comparable with the intraperitoneal route. MS152 treatment in newborns ameliorates the perinatal lethality and poor growth, maintaining reactivation in a PWS mouse model at postnatal 90 days. Our findings provide strong support for MS152 as a first-in-class inhibitor to advance the epigenetic therapy of PWS in humans.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prader-Willi SyndromeEpigenesis, GeneticDisease Models, AnimalHumansAnimalsMiceAdministration, OralHistocompatibility AntigensBrainHistone-Lysine N-Methyltransferase

Stichwörter der Autor:innen

EHMT2H3K9 methyl transferaseH3K9me1/2Histone modificationPrader-willi syndromeSnord116Snrpnepigenetic therapyimrpinting disorderpharmacological intervention

Substanzen

EHMT2 protein, humanHistocompatibility AntigensHistone-Lysine N-Methyltransferase

Autor:innen und Institutionen

  • Department of Genetics, Yale University School of Medicine, 333 Cedar Street, New Haven CT 06520, USA.
  • Mount Sinai Center for Therapeutics Discovery, Departments of Pharmacological Sciences, Oncological Sciences and Neuroscience, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.
  • Department of Laboratory Medicine and Genetics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul 06351, South Korea.
  • Mount Sinai Center for Therapeutics Discovery, Departments of Pharmacological Sciences, Oncological Sciences and Neuroscience, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA. El…
  • Department of Genetics, Yale University School of Medicine, 333 Cedar Street, New Haven CT 06520, USA; Department of Neuroscience, Yale University School of Medicine, 333 Cedar Street, New Haven CT 06520, USA; Departmen…

Förderung

  • NIH HHS
  • NCATS NIH HHS
  • NICHD NIH HHS
  • NCI NIH HHS
  • NIMH NIH HHS
  • NIA NIH HHS
  • National Research Foundation of Korea
  • Celgene

Zitieren

APA

Wang, S. E., Xiong, Y., Jang, M. A., Park, K. S., Donahue, M., Velez, J., Jin, J., & Jiang, Y. H. (2024). Newly developed oral bioavailable EHMT2 inhibitor as a potential epigenetic therapy for Prader-Willi syndrome. Molecular Therapy. https://doi.org/10.1016/j.ymthe.2024.05.034

Vancouver

Wang SE, Xiong Y, Jang MA, Park KS, Donahue M, Velez J, et al. Newly developed oral bioavailable EHMT2 inhibitor as a potential epigenetic therapy for Prader-Willi syndrome. Molecular Therapy. 2024. doi:10.1016/j.ymthe.2024.05.034

BibTeX
@article{Wang2024,
  author = {Wang, Sung Eun and Xiong, Yan and Jang, Mi-Ae and Park, Kwang-Su and Donahue, Meaghan and Velez, Julia and Jin, Jian and Jiang, Yong-Hui},
  title = {Newly developed oral bioavailable EHMT2 inhibitor as a potential epigenetic therapy for Prader-Willi syndrome},
  journal = {Molecular Therapy},
  year = {2024},
  doi = {10.1016/j.ymthe.2024.05.034}
}
Kostenlos starten →